Other

Allegheny University of the Health Sciences

Symbiotec Gesellschaft Zur Erforschung Und Entwicklung Auf Dem Gebiet Der Biotechnologic Mbh

Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der

Michael Zeppezauer

Reiner Class

Robert Reichhart

Hans-Peter Leinenbach

Hans Jornvall

Volker Rusch

Arno Sch&ouml;nberger

Hans P Leinenbach

Ladislav Cebecauer

Cordula Fassbender

A therapeutic or prophylactic agent for cancer is disclosed which damages the membrane and kills cancer cells, in particular of the blood-forming system, having membrane protein aggregates which contain several core histones or largely core-like histones and/or their parts. The therapeutic or prophylactic agent contains at least one pure histone or its active sequence section selected from the group composed of histone H1, H1 subtypes, H2A, H2B, H2A:H2B dimer, H3 and H4, covalent modified histones of the above-mentioned type and/or their active sections and functionally and structurally similar proteins (protamines, histone-like proteins of prokaryotic and archae bacteria).

Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties

Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from systemic lupus erythematosus (SLE). In the case of the peptides it is preferably a question of the C terminus of H1 with the sequence section 187-211 and the N termini of H2B with the sequence sections 1-35 and 36-76, which are capable of cross reactions with the autoantibodies (anti-histone-antibodies). The invention furthermore provides ways of forming monoclonal antibodies and antiidiotypical antibodies, which are directed against autoantibodies. The diagnosis of SLE is possible in accordance with the invention with a high degree of certainty and the monoclonal antibodies directed against the autoantibodies are suitable for the production of medicaments for the therapy of SLE.

Peptides for the production of preparations for the diagnosis and therapy of systemic lupus

A therapeutic method for treatment of carcinoma or autoimmune diseases of a patient, which includes administering to said patient a biologically active composition which comprises a therapeutically acceptable carrier and, in a quantity having a therapeutic effect, two active substances comprising a pure cytostatic drug as the first active substance and a biologically active pure histone selected from the group consisting of H1, H2A, H2B, H2A:H2B, and H3 as the second active substance, providing a synergistic action of both of said active substances at a site of pathogenic process of said patient.

Therapeutic method for treatment of carcinoma or autoimmune diseases

According to this invention the combination of active substances for use in therapeutic procedures consists of at least one cytostatic compound, e.g. vincristine, methotrexate, cisplatin as the first agent and at least one histone and/or one active histone fragment with cytostatic or cytotoxic activity as the second agent. Both active agents act synergistically at the site of the pathogenic process.

Cytostatic or cytotoxic combination of active substances for use in

The invention relates to the use of pure histones H1, H2A, H2B, H2A:H2B, H3 as hormonal or hormon-like active substance for the preparation of pharmaceuticals for the immuno-therapy, for the therapy of endocrine disturbance and for cancer therapy. Instead of the histones also their evolutionary variable sections or at least one partial section of at least five aminoacid residues of at least one evolutionary variable histon section can be used.

Use of pure histones H1 and H2A:H2B dimers in therapeutic methods

Biologically active substance with hormonal properties, production

Growing community of inventors

Scheidt, Germany

Michael Zeppezauer